Prognostic value of combined WT1 and multiparameter flow cytometry assessment for measurable residual disease after induction in non-APL acute myeloid leukemia

References

• Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392(10147):593–606. doi: 10.1016/S0140-6736(18)31041-9.
   PubMed Web of Science ®Google Scholar
• Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378(13):1189–1199. doi: 10.1056/NEJMoa1716863.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221. doi: 10.1056/NEJMoa1516192.
   PubMed Web of Science ®Google Scholar
• Al-Mawali A, Gillis D, Lewis I. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse. Cytometry B Clin Cytom. 2009;76(2):91–101. doi: 10.1002/cyto.b.20444.
   PubMedGoogle Scholar
• Cluzeau T, Lemoli RM, McCloskey J, et al. Measurable residual disease in High-Risk acute myeloid leukemia. Cancers. 2022;14(5):1278. doi: 10.3390/cancers14051278.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi: 10.1182/blood-2016-08-733196.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Vidriales MB, Lopez-Berges C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood. 2001;98(6):1746–1751. doi: 10.1182/blood.v98.6.1746.
   PubMed Web of Science ®Google Scholar
• Kern W, Bacher U, Haferlach C, et al. The role of multiparameter flow cytometry for disease monitoring in AML. Best Pract Res Clin Haematol. 2010;23(3):379–390. doi: 10.1016/j.beha.2010.06.007.
   PubMed Web of Science ®Google Scholar
• Loken MR, Alonzo TA, Pardo L, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from children’s oncology group. Blood. 2012;120(8):1581–1588. doi: 10.1182/blood-2012-02-408336.
   PubMed Web of Science ®Google Scholar
• Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe against cancer program. Leukemia. 2003;17(12):2318–2357. doi: 10.1038/sj.leu.2403135.
   PubMed Web of Science ®Google Scholar
• Mencia-Trinchant N, Hu Y, Alas MA, et al. Minimal residual disease monitoring of acute myeloid leukemia by massively multiplex digital PCR in patients with NPM1 mutations. J Mol Diagn. 2017;19(4):537–548. doi: 10.1016/j.jmoldx.2017.03.005.
   PubMed Web of Science ®Google Scholar
• Kasprzyk A, Secker-Walker LM. Increased sensitivity of minimal residual disease detection by interphase FISH in acute lymphoblastic leukemia with hyperdiploidy. Leukemia. 1997;11(3):429–435. doi: 10.1038/sj.leu.2400589.
   PubMed Web of Science ®Google Scholar
• Engel H, Drach J, Keyhani A, et al. Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells. Leukemia. 1999;13(4):568–577. doi: 10.1038/sj.leu.2401359.
   PubMed Web of Science ®Google Scholar
• Waalkes A, Penewit K, Wood BL, et al. Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes. Haematologica. 2017;102(9):1549–1557. doi: 10.3324/haematol.2017.169136.
   PubMed Web of Science ®Google Scholar
• Hourigan CS, Dillon LW, Gui G, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38(12):1273–1283. doi: 10.1200/JCO.19.03011.
   PubMed Web of Science ®Google Scholar
• Voskova D, Schoch C, Schnittger S, et al. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings. Cytometry B Clin Cytom. 2004;62(1):25–38. doi: 10.1002/cyto.b.20025.
   PubMedGoogle Scholar
• Sui JN, Chen QS, Zhang YX, et al. Identifying leukemia-associated immunophenotype-based individualized minimal residual disease in acute myeloid leukemia and its prognostic significance. Am J Hematol. 2019;94(5):528–538. doi: 10.1002/ajh.25431.
   PubMed Web of Science ®Google Scholar
• Zeijlemaker W, Gratama JW, Schuurhuis GJ. Tumor heterogeneity makes AML a "moving target" for detection of residual disease. Cytometry. 2013;86:3–14. doi: 10.1002/cytob.21134.
   PubMedGoogle Scholar
• Grimwade D, Freeman SD. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"? Blood. 2014;124(23):3345–3355. doi: 10.1182/blood-2014-05-577593.
   PubMed Web of Science ®Google Scholar
• Cilloni D, Gottardi E, De Micheli D, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia. 2002;16(10):2115–2121. doi: 10.1038/sj.leu.2402675.
   PubMed Web of Science ®Google Scholar
• Weisser M, Kern W, Rauhut S, et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia. 2005;19(8):1416–1423. doi: 10.1038/sj.leu.2403809.
   PubMed Web of Science ®Google Scholar
• Rossi G, Minervini MM, Melillo L, et al. Predictive role of minimal residual disease and log clearance in acute myeloid leukemia: a comparison between multiparameter flow cytometry and wilm’s tumor 1 levels. Ann Hematol. 2014;93(7):1149–1157. doi: 10.1007/s00277-014-2029-9.
   PubMed Web of Science ®Google Scholar
• Zhou M, An FR, Zhang Q[, et al. A Real-World study of the effect of rhG-CSF on clinical efficacy and flow cytometry MRD after initial induction therapy for acute myeloid leukemia. ]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022;30:1022–1027.
   PubMedGoogle Scholar
• Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a european LeukemiaNet study. J Clin Oncol. 2009;27(31):5195–5201. doi: 10.1200/JCO.2009.22.4865.
   PubMed Web of Science ®Google Scholar
• Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the european LeukemiaNet MRD working party. Blood. 2018;131(12):1275–1291. doi: 10.1182/blood-2017-09-801498.
   PubMed Web of Science ®Google Scholar
• Ostergaard M, Olesen LH, Hasle H, et al. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-Centre study. Br J Haematol. 2004;125(5):590–600. doi: 10.1111/j.1365-2141.2004.04952.x.
   PubMed Web of Science ®Google Scholar
• Dulery R, Nibourel O, Gauthier J, et al. Impact of wilms’ tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML. Bone Marrow Transplant. 2017;52(4):539–543. doi: 10.1038/bmt.2016.318.
   PubMed Web of Science ®Google Scholar
• Lyu X, Xin Y, Mi R, et al. Overexpression of wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia. PLoS One. 2014;9(3):e92470. doi: 10.1371/journal.pone.0092470.
   PubMed Web of Science ®Google Scholar
• Depreter B, Philippe J, Meul M, et al. Cancer-related mRNA expression analysis using a novel flow cytometry-based assay. Cytometry B Clin Cytom. 2018;94(4):565–575. doi: 10.1002/cyto.b.21593.
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Fujita H, Fujimaki K, et al. Clinical significance of minimal residual disease detected by multidimensional flow cytometry: serial monitoring after allogeneic stem cell transplantation for acute leukemia. Leuk Res. 2012;36(8):998–1003. doi: 10.1016/j.leukres.2012.04.005.
   PubMed Web of Science ®Google Scholar
• Zhang R, Yang JY, Sun HQ, et al. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia. Eur Rev Med Pharmacol Sci. 2015;19:2679–2688.
   PubMed Web of Science ®Google Scholar
• Rossi G, Minervini MM, Carella AM, et al. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets. Leuk Res. 2012;36(4):401–406. doi: 10.1016/j.leukres.2011.11.020.
   PubMed Web of Science ®Google Scholar
• Mashima K, Oh I, Ikeda T, et al. Role of sequential monitoring of WT1 gene expression in patients with acute myeloid leukemia for the early detection of leukemia relapse. Clin Lymphoma Myeloma Leuk. 2018;18(12):e521–e527. doi: 10.1016/j.clml.2018.07.298.
   PubMed Web of Science ®Google Scholar
• Lambert J, Lambert J, Thomas X, et al. Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML. Blood Adv. 2021;5(23):5258–5268. doi: 10.1182/bloodadvances.2021004322.
   PubMed Web of Science ®Google Scholar
• Candoni A, De Marchi F, Zannier ME, et al. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission. Leuk Res. 2017;63:22–27. doi: 10.1016/j.leukres.2017.10.010.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Othus M, Walter RB, et al. Deep NPM1 sequencing following allogeneic hematopoietic cell transplantation improves risk assessment in adults with NPM1-Mutated AML. Biol Blood Marrow Transplant. 2018;24(8):1615–1620. doi: 10.1016/j.bbmt.2018.04.017.
   PubMed Web of Science ®Google Scholar
• Patkar N, Kakirde C, Shaikh AF, et al. Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML). Leukemia. 2021;35(5):1392–1404. doi: 10.1038/s41375-021-01131-6.
   PubMed Web of Science ®Google Scholar
• Fang M, Storer B, Wood B, et al. Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. Cancer. 2012;118(9):2411–2419. doi: 10.1002/cncr.26539.
   PubMed Web of Science ®Google Scholar
• Liu FJ, Cheng WY, Lin XJ, et al. Measurable residual disease detected by multiparameter flow cytometry and sequencing improves prediction of relapse and survival in acute myeloid leukemia. Front Oncol. 2021;11:677833. doi: 10.3389/fonc.2021.677833.
   PubMed Web of Science ®Google Scholar